Yahoo Finance Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX)
Michelle Gilson, Chief Financial Officer of Arcellx Inc (NASDAQ:ACLX), sold 12,121 shares of the company on May 24, 2024. The transaction was detailed in a recent SEC Filing. Following this transaction, the insider now owns 19,792 shares of the company.
Over the past year, Michelle Gilson has engaged in multiple transactions involving the company's stock, selling a total of 42,164 shares. No purchases were recorded for the insider during this period.
Arcellx Inc (NASDAQ:ACLX) is a biotechnology firm focused on the development of novel cell therapies for the treatment of cancer and other severe diseases. The company's innovative approach aims to harness the power of cells to fight disease more effectively.
On the date of the latest transaction, shares of Arcellx Inc were priced at $50.71 each. The company's market cap stood at approximately $2.78 billion.
The insider transaction history for Arcellx Inc shows a trend of more sales than purchases among insiders over the past year, with 20 recorded sales and no insider buys.
For investors monitoring insider behaviors, such trends and transactions are significant, especially when considering the company's valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This insider sale could be of interest to stakeholders and potential investors, providing insights into insider confidence and potential future stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
